Peptonic Medical’s rights issue heavily oversubscribed
Stockholm, May 8th, 2018 - The Board of Peptonic Medical AB (publ) (’Peptonic’ or ’Company’) today announced that the rights issue of 12.5 MSEK with pre-emptive rights for existing shareholders has been oversubscribed.
subscribed for with pre-emptive rights representing 93% of the issue. Another 9.8 MSEK was subscribed for without pre-emptive rights equalling 78% of the issue. Underwriters will not have to take up any shares. Subscribers without pre-emptive rights will receive contract notes for payment on May 14th, 2018. The new shares are expected to be allocated to respective subscribers on May 25th, 2018. Until then temporary shares will be issued, so called ’BTAs’, with last trading day on May 23rd, 2018.
Issue price was 0.29 SEK per share. The number of shares will increase from 43 014 300 to 86 028 600 after registration, while registered share capital will increase from 4 301 43.,00 SEK to 8 602 86.,00 SEK.
The share (ticker: PMED) is listed on Aktietorget (www.aktietorget.se) with ISIN no SE0005962206.
”We are pleased to note that the rights issue was very well received by the market. As judged by the many inquiries by previous study patients, there is a great interest in VagiVital® among future users. The positive outcome of the rights issue also shows that there is a strong support for our business model. We are now waiting for the CE mark for VagiVital®, and after that, we look forward to launching the product”, says Johan Inborr, CEO of Peptonic Medical.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
Partner Fondkommission AB acted as financial advisors to Peptonic Medical in this rights issue.
About Peptonic Medical
Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women specific diseases and medical conditions.
VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com
VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results for both subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) and objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
Peptonic Medical plans to launch VagiVital® as a non-prescription self-care product in 2018.